Table 1. Baseline characteristics of patients with HBeAg-positive chronic hepatitis B infection after 48 weeks of PegIFN therapy.
| No sustained HBeAg seroconversion (n = 80) | Sustained HBeAg seroconversion(n = 31) | p-value | |
|---|---|---|---|
| Male, n (%) | 59 (72.8%) | 20 (66.7%) | 0.64 |
| Age (years), mean ± SD | 39.1 ± 11.3 | 42.5 ± 11.2 | 0.13 |
| Body mass index (kg/m2), mean ± SD | 23.6 ± 3.6 | 24.0 ± 3.2 | |
| HBV genotype, n (%) | |||
| B | 12 (15.8%) | 1 (3.4%) | |
| C | 63 (82.9%) | 28 (96.6%) | 0.09 |
| D | 1 (1.3%) | 0 | |
| Cirrhosis, n (%) | 6 (7.7%) | 3 (11.1%) | 0.13 |
| Pre-treatment HBV DNA (logIU/ml), mean ± SD | 7.3 ± 1.3 | 6.6 ± 1.5 | 0.006 |
| Pre-treatment HBsAg level (logIU/ml), mean ± SD | 3.9 ± 1.0 | 3.5 ± 0.7 | 0.004 |
| Pre-treatment ALT (U/L), mean ± SD | 95.7 ± 76.1 | 122.3 ± 91.8 | 0.04 |
PegIFN, pegylated interferon; HBV, hepatitis B virus; ALT, alanine aminotransferase; SD, standard deviation.